Search
Bioallethrin
go.drugbank.com/drugs/DB13746ApprovedWithdrawnA mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. … Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients.
Esketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. … [L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications
Lauric acid
go.drugbank.com/drugs/DB03017ApprovedLauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses. … Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression.
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[L938] A month later, inotuzumab ozogamicin was also approved by the FDA.[L50542] … Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigational[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Sunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalOn January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs.
Talimogene laherparepvec
go.drugbank.com/drugs/DB13896ApprovedInvestigationalIt was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma.
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigationalCollagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.